管状腺:放疗中潜在的新危及器官
该研究基于PSMA PET/CT在鼻咽部发现双侧大唾液腺位置,100例前列腺或尿道腺癌患者均可见该PSMA阳性区域,尸体解剖证实为黏液腺;在723例头颈癌患者中,该腺体区域平均放疗剂量与12个月医生评价的≥2级口干和吞咽困难显著相关。
要点
- 鼻咽部存在双侧PSMA阳性大唾液腺,平均长度4 cm,命名为管状腺。
- 头颈癌患者该腺体区域平均剂量与12个月≥2级口干和吞咽困难显著相关。
- 放疗中保护管状腺可能改善患者生活质量。
核心结论
- 人体存在一对先前被忽视且临床相关的宏观唾液腺位置,建议命名为管状腺。
- 放疗中保护这些腺体可能为改善患者生活质量提供机会。
研究设计与样本
- 回顾性队列评估100例连续扫描的前列腺或尿道腺癌患者PSMA阳性区域。
- 尸体研究(n=2)评估形态学和组织学特征。
- 回顾性分析723例头颈癌患者前瞻性收集的临床数据,用多变量逻辑回归评估放疗剂量与口干或吞咽困难的关系。
主要发现
- 全部100例患者均显示边界清晰的双侧PSMA阳性区域,平均长度4 cm。
- 组织学和3D重建证实存在表达PSMA、以黏液腺为主、伴多个引流管的腺体,主要位于咽鼓管圆枕附近。
- 头颈癌患者中,腺体区域平均放疗剂量与12个月医生评价的≥2级口干显著相关(0.019/gy,95%CI 0.005-0.033,p = .007)。
- 头颈癌患者中,腺体区域平均放疗剂量与12个月医生评价的≥2级吞咽困难显著相关(0.016/gy,95%CI 0.001-0.031,p = .036)。
- 24个月随访结果相似。
临床怎么用
- 在头颈癌放疗计划中考虑将管状腺作为潜在危及器官进行保护。
局限性
- 尸体研究样本量仅2例。
- 头颈癌患者数据为回顾性分析前瞻性收集的临床数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The presence of previously unnoticed bilateral macroscopic salivary gland locations in the human nasopharynx was suspected after visualization by positron emission tomography/computed tomography with prostate-specific membrane antigen ligands (PSMA PET/CT). We aimed to elucidate the characteristics of this unknown entity and its potential clinical implications for radiotherapy. MATERIALS AND METHODS: The presence and configuration of the PSMA-positive area was evaluated in a retrospective cohort of consecutively scanned patients with prostate or urethral gland cancer (n = 100). Morphological and histological characteristics were assessed in a human cadaver study (n = 2). The effect of radiotherapy (RT) on salivation and swallowing was retrospectively investigated using prospectively collected clinical data from a cohort of head-neck cancer patients (n = 723). With multivariable logistic regression analysis, the association between radiotherapy (RT) dose and xerostomia or dysphagia was evaluated. RESULTS: All 100 patients demonstrated a demarcated bilateral PSMA-positive area (average length 4 cm). Histology and 3D reconstruction confirmed the presence of PSMA-expressing, predominantly mucous glands with multiple draining ducts, predominantly near the torus tubarius. In the head-neck cancer patients, the mean RT dose to the gland area was significantly associated with physician-rated post-treatment xerostomia and dysphagia ≥ grade 2 at 12 months (0.019/gy, 95%CI 0.005-0.033, p = .007; 0.016/gy, 95%CI 0.001-0.031, p = .036). Follow-up at 24 months had similar results. CONCLUSION: The human body contains a pair of previously overlooked and clinically relevant macroscopic salivary gland locations, for which we propose the name tubarial glands. Sparing these glands in patients receiving RT may provide an opportunity to improve their quality of life.
引用
- Valstar MH, de Bakker BS, Steenbakkers RJHM, et al. The tubarial salivary glands: A potential new organ at risk for radiotherapy. Radiother Oncol. 2020. PMID: 32976871. doi:10.1016/j.radonc.2020.09.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。